Cargando…
Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey
Background: Sickle cell disease, the inherited blood disorder characterized by anemia, severe pain and other vaso-occlusive complications, acute chest syndrome, disproportionate hospitalization, and early mortality, has significant financial, social, and psychosocial impacts and drains individuals,...
Autores principales: | Okocha, Emmanuel Chide, Gyamfi, Joyce, Ryan, Nessa, Babalola, Oluwatoyin, Etuk, Eno-Abasi, Chianumba, Reuben, Nwegbu, Maxwell, Isa, Hezekiah, Madu, Anazoeze Jude, Adegoke, Samuel, Nnebe-Agumandu, Uche, Brown, Biobele, Peprah, Emmanuel, Nnodu, Obiageli E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807646/ https://www.ncbi.nlm.nih.gov/pubmed/35126450 http://dx.doi.org/10.3389/fgene.2021.765958 |
Ejemplares similares
-
Determinants of hydroxyurea use among doctors, nurses and sickle cell
disease patients in Nigeria
por: Isa, Hezekiah Alkali, et al.
Publicado: (2022) -
Outcome of Hydroxyurea Use in SCD and Evaluation of Patients’ Perception and Experience in Nigeria
por: Chianumba, Reuben Ikechukwu, et al.
Publicado: (2022) -
Strategies to improve healthcare services for patients with sickle cell disease in Nigeria: The perspectives of stakeholders
por: Isa, Hezekiah, et al.
Publicado: (2023) -
Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability
por: Ryan, Nessa, et al.
Publicado: (2020) -
HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: Promises and challenges
por: Nnodu, Obiageli, et al.
Publicado: (2019)